Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc. (Prestige) sells over-the-counter healthcare, household cleaning and personal care products in a global marketplace. The Company’s products are sold through multiple channels, including mass merchandisers and drug, grocery, dollar and club stores, which allow it to launch products across all distribution channels and reduce its exposure to any single distribution channel. The Company conducts its operations through three principal business segments: over-the-counter healthcare, household cleaning and personal care. During the fiscal year ended March 31, 2009 (fiscal 2009), Prestige’s principal brands accounted for approximately 94.5% of its net revenues.

Vernalis plc company was founded in 1986 and is based in Winnersh, the United Kingdom. Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America. It primarily involves in the research, development, and commercialization of pharmaceutical products for a range of medical disorders. The company’s products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinson’s disease symptoms associated with advanced Parkinson’s disease. Its product pipeline comprises V3381/Indantadol, a Phase IIb study novel small molecule with a dual mechanism for the treatment of neuropathic pain; V85546, a Phase I study selective MMP 12 inhibitor for inflammation; V1512/Levodopa methyl ester/carbidopa, a Phase II trial product for Parkinson’s disease treatment; V2006, an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinson’s disease; NVP-AUY922, a novel Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers; V158866 Fatty Acid Amide Hydrolase, a pre-clinical stage product for pain management; V10153, a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke; and V24343, a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.

Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders.

IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE Biotechnology, Inc. engages in the development, production, and marketing of specialty biochemical products in the United States and internationally. It focuses on research and development in the areas of fermentation technology, nutrition and health, and marketing of products and applications. The company offers AstaXin, a natural source of astaxanthin, a pigment that imparts the characteristic red color to the flesh of salmon, trout, prawns, and other types of fish and shellfish. It is also venturing to supply astaxanthin as a nutraceutical ingredient. The company sells AstaXin primarily to fish producers in the aquaculture industry principally in the European Union, Japan, Chile, and Canada. IGENE Biotechnology, Inc. has a joint venture agreement with Archer-Daniels-Midland Company to manufacture and sell astaxanthin and derivative products worldwide.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis.Cornerstone Therapeutics company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

APP Pharmaceuticals, a company that develops, makes, and markets anesthetics and other injectable drugs. Specializing in generics, APP's critical care products segment includes market-leading general anesthetic Diprivan and blood thinner Heparin. Other product segments focus on injectable oncology treatments and drugs that fight ear, heart, respiratory tract, skin, and sinus infections. APP markets through a direct sales force and often sells through group purchasing organizations to customers that include hospitals, long-term care facilities, and clinics in North America. APP Pharmaceuticals, LLC company is a subsidiary of German medical firm Fresenius.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors own a controlling stake in the company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.